LAB282, the drug discovery partnership for Oxford University, has made its second round of awards to support promising life sciences ideas with market potential emerging from the University.

LAB282 is providing critical early stage guidance and industry validation to novel therapeutic concepts, and leveraging them with a £13m drug discovery fund.

Out of a potential seven candidates, LAB282 decided to support five with awards ranging into six-figure sums.

See the full release here

Lab282 Partners